Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review

References

• Al Saabi A, Allorge D, Sauvage FL, et al. (2013). Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos 41:568–574
   PubMed Web of Science ®Google Scholar
• Ashton CH. (2001). Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 178:101–106
   PubMed Web of Science ®Google Scholar
• Ben Amar M. (2006). Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105:1–25
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Nguyen TL, Jones RT, et al. (1980). Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28:115–120
   PubMed Web of Science ®Google Scholar
• Bland TM, Haining RL, Tracy TS, Callery PS. (2005). CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096–1103
   PubMed Web of Science ®Google Scholar
• Bornheim LM, Lasker JM, Raucy JL. (1992). Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab Dispos 20:241–246
   PubMed Web of Science ®Google Scholar
• Chetty M, Miller R, Moodley SV. (1994). Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol 46:523–526
   PubMed Web of Science ®Google Scholar
• Chimalakonda KC, Bratton SM, Le VH, et al. (2011). Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 39:1967–1976
   PubMed Web of Science ®Google Scholar
• Chimalakonda KC, Seely KA, Bratton SM, et al. (2012). Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174–2184
   PubMed Web of Science ®Google Scholar
• Coutselinis A, Michalodimitrakis M. (1981). Acetylcholinesterase activity after hashish smoking. Clin Toxicol 18:385–387
   PubMed Web of Science ®Google Scholar
• Dresen S, Ferreiros N, Putz M, et al. (2010). Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194
   PubMed Web of Science ®Google Scholar
• ElSohly MA, Slade D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78:539–548
   PubMed Web of Science ®Google Scholar
• Engels FK, de Jong FA, Sparreboom A, et al. (2007). Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12:291–300
   PubMed Web of Science ®Google Scholar
• Fattore L, Fratta W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647
   Web of Science ®Google Scholar
• Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. (1983). Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol 16:271–280
   PubMed Web of Science ®Google Scholar
• Hazecamp A, Ware MA, Muller-Vahl KR, et al. (2013). The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms. J Psychoactive Drugs 45:199–219
   PubMed Web of Science ®Google Scholar
• Holland ML, Allen JD, Arnold JC. (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 591:128–131
   PubMed Web of Science ®Google Scholar
• Holland ML, Lau DT, Allen JD, Arnold JC. (2007). The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 152:815–824
   PubMed Web of Science ®Google Scholar
• Huestis MA. (2007). Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770–1804
   PubMed Web of Science ®Google Scholar
• Jiang R, Yamaori S, Takeda S, et al. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165–170
   PubMed Web of Science ®Google Scholar
• Johansson E, Ohlsson A, Lindgren JE, et al. (1987). Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 14:495–499
   PubMedGoogle Scholar
• Jusko WJ, Gardner MJ, Mangione A, et al. (1979). Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci 68:1358–1366
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Schentag JJ, Clark JH, et al. (1978). Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther 24:405–410
   PubMedGoogle Scholar
• Kosel BW, Aweeka FT, Benowitz NL, et al. (2002). The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:543–550
   PubMed Web of Science ®Google Scholar
• Markianos M, Stefanis C. (1982). Effects of acute cannabis use and short-term deprivation on plasma prolactin and dopamine-beta-hydroxylase in long-term users. Drug Alcohol Depend 9:251–255
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Kishi N, Higuchi S, et al. (2000). CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 28:1291–1296
   PubMed Web of Science ®Google Scholar
• Mazor M, Dvilansky A, Aharon M, et al. (1982). Effect of cannabinoids on the activity of monoamine oxidase in normal human platelets. Arch Int Physiol Biochim 90:15–20
   PubMed Web of Science ®Google Scholar
• Mazur A, Lichti CF, Prather PL, et al. (2009). Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37:1496–1504
   PubMed Web of Science ®Google Scholar
• Mehmedic Z, Chandra S, Slade D, et al. (2010). Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217
   PubMed Web of Science ®Google Scholar
• Mwenifumbo JC, Sellers EM, Tyndale RF. (2007). Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug Alcohol Depend 89:24--33
   Google Scholar
• Nadulski T, Pragst F, Weinberg G, et al. (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799–810
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Andersson S, et al. (1986). Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77–83
   PubMedGoogle Scholar
• Ohlsson A, Lindgren JE, Wahlen A, et al. (1982). Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9:6–10
   PubMedGoogle Scholar
• Pacher P, Batkai S, Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462
   PubMed Web of Science ®Google Scholar
• Pertwee RG. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol Rev 62:588–631
   PubMed Web of Science ®Google Scholar
• Richardson TH, Jung F, Griffin KJ, et al. (1995). A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87–96
   PubMed Web of Science ®Google Scholar
• Roth MD, Marques-Magallanes JA, Yuan M, et al. (2001). Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24:339–344
   PubMed Web of Science ®Google Scholar
• Sachse-Seeboth C, Pfeil J, Sehrt D, et al. (2009). Interindividual variation in the pharmacokinetics of delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273–276
   PubMed Web of Science ®Google Scholar
• Schurr A, Rigor BM. (1984). Cannabis extract, but not delta 1-tetrahydrocannabinol, inhibits human brain and liver monoamine oxidase. Gen Pharmacol 15:171–174
   PubMedGoogle Scholar
• Shultz M. (2007). Comparing test searches in PubMed and Google Scholar. J Med Libr Assoc 95:442–445
   PubMed Web of Science ®Google Scholar
• Srivastava N, Sharma RK, Singh N, Sharma B. (2012). Acetylcholinesterase from human erythrocytes membrane: A screen for evaluating the activity of some traditional plant extracts. Cell Mol Biol (Noisy-le-grand) 58:160–169
   PubMed Web of Science ®Google Scholar
• Stillman RC, Wyatt RJ, Murphy DL, Rauscher FP. (1978). Low platelet monoamine oxidase activity and chronic marijuana use. Life Sci 23:1577–1581
   PubMed Web of Science ®Google Scholar
• Tournier N, Chevillard L, Megarbane B, et al. (2010). Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 13:905–915
   PubMed Web of Science ®Google Scholar
• UNODC. (2012). United Nations office on drugs and crime. World Drug Report 2012, United Nations, New York, NY
   Google Scholar
• Watanabe K, Matsunaga T, Kimura T, et al. (2002). Major cytochrome P450 enzymes responsible for microsomal aldehyde oxygenation of 11-oxo-Delta8-tetrahydrocannabinol and 9-anthraldehyde in human liver. Drug Metab Pharmacokinet 17:516–521
   PubMedGoogle Scholar
• Watanabe K, Matsunaga T, Yamamoto I, et al. (1995). Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138–1141
   PubMed Web of Science ®Google Scholar
• Watanabe K, Yamaori S, Funahashi T, et al. (2007). Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415–1419
   PubMed Web of Science ®Google Scholar
• Yamamoto I, Narimatsu S, Shimonishi T, et al. (1984). Difference in epoxides formation and their further metabolism between delta 9- and delta 8-tetrahydrocannabinols by human liver microsomes. J Pharmacobiodyn 7:254–262
   PubMedGoogle Scholar
• Yamaori S, Ebisawa J, Okushima Y, et al. (2011a). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:730–736
   PubMed Web of Science ®Google Scholar
• Yamaori S, Koeda K, Kushihara M, et al. (2012). Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27:294–300
   PubMed Web of Science ®Google Scholar
• Yamaori S, Kushihara M, Yamamoto I, Watanabe K. (2010). Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691–1698
   PubMed Web of Science ®Google Scholar
• Yamaori S, Maeda C, Yamamoto I, Watanabe K. (2011b). Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 29:117–124
   Web of Science ®Google Scholar
• Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. (2011c). Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39:2049–2056
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, et al. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 317:850–857
   PubMed Web of Science ®Google Scholar